Geron Adds Biopharma Veterans As RYTELO Focus And Valuation Draw Attention [Yahoo! Finance]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Yahoo! Finance
Geron (NasdaqGS:GERN) appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. Both executives bring extensive experience in commercial-stage biopharmaceuticals and product launches. The appointments come as Geron focuses on introducing and expanding its blood cancer treatment, RYTELO. Geron is a commercial-stage biopharmaceutical company focused on therapies for blood cancers, with RYTELO as its key product. Bringing in board members with a background in commercial execution and product commercialization aligns with the company's current phase, where launch decisions and market positioning can influence how a new therapy gains traction. For investors watching NasdaqGS:GERN, these board changes highlight management's focus on execution around RYTELO and long-term value creation goals. The added experience in scaling commercial operations and guiding biopharmaceutical boards may influence how Geron prioritizes resources, partnerships, and growth init
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron Adds Chief Legal Officer As Equity Ties To Execution Risk [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf [Yahoo! Finance]Yahoo! Finance
- Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewswire
- Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
GERN
Earnings
- 2/25/26 - Miss
GERN
Sec Filings
- 4/14/26 - Form 4
- 4/14/26 - Form 3
- 4/7/26 - Form ARS
- GERN's page on the SEC website